-
Summarizing the Intentions and Outcomes of JUO 2023 Issue 3
- Cheol Kwak
-
J Urol Oncol. 2023;21(3):181-182.
-
Editorial
Nov 30, 2023
|
-
Influence of Body Composition on the Perioperative and Survival Outcomes of Renal Cell Carcinoma
- Edouard H. Nicaise, Benjamin N. Schmeusser, Yash B. Shah, et al.
-
J Urol Oncol. 2023;21(3):183-199.
-
Invited Review
Nov 30, 2023
Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
|
-
Preoperative Renal Artery Embolization Before Radical Nephrectomy for Nonmetastatic Renal Cell Carcinoma: A Propensity Score Matched Analysis
- Jin Noh, Sang Hun Song, Gyoohwan Jung, et al.
-
J Urol Oncol. 2023;21(3):200-207.
-
Topic Article
Nov 30, 2023
Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
|
-
The Future of Adjuvant Therapy in Renal Cell Carcinoma: Recent Insights and Prospects
- Hyerim Ha, Joo Han Lim
-
J Urol Oncol. 2023;21(3):208-216.
-
Invited Review
Nov 30, 2023
Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
|
-
Role of Radiotherapy in Metastatic Renal Cell Carcinomas: An Evolutionary Journey in a Misunderstood Histological Type
- Chan Woo Wee, Jaeho Cho
-
J Urol Oncol. 2023;21(3):217-227.
-
Invited Review
Nov 30, 2023
Perioperative Considerations and Treatment for Advanced Renal Cell Carcinoma
|
-
Optimal Management of Bacillus Calmette-Guérin–Refractory Non–Muscle-Invasive Bladder Cancer in 2023
- Jiwoong Yu, Hyun Hwan Sung
-
J Urol Oncol. 2023;21(3):228-240.
-
Invited Review
Nov 30, 2023
Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
|
-
Early Experience With Pembrolizumab in Bacillus Calmette-Guérin Unresponsive Non–Muscle-Invasive Bladder Cancer
- Chung Un Lee, Wan Song, Minyong Kang, et al.
-
J Urol Oncol. 2023;21(3):241-248.
-
Topic Article
Nov 30, 2023
Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
|
-
Clinical Outcomes of Patients With Variant Histology of Urothelial Carcinoma After Radical Cystectomy
- Dan Bee Lee, Jae Yeon Kim, Yun Ha Lee, et al.
-
J Urol Oncol. 2023;21(3):249-256.
-
Original Article
Nov 30, 2023
Optimal Management for BCG Unresponsive Non-Muscle-Invasive Bladder Cancer
|
-
Predictive Factors of Abiraterone Response in Patients With High-Risk Metastatic Hormone-Sensitive Prostate Cancer
- Jaeyoung Cho, Jungyo Suh, Dalsan You, et al.
-
J Urol Oncol. 2023;21(3):257-263.
-
Topic Article
Nov 30, 2023
Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
|
-
Nonregional Lymph Node Metastasis as a Predictor of Early Progression When Using Androgen Receptor Targeting Agents in Patients With Metastatic Castration-Resistant Prostate Cancer Without Previous Chemotherapy
- Sihyeon Kim, Beom Yong Rho, Dong Hyuk Kang, et al.
-
J Urol Oncol. 2023;21(3):264-270.
-
Topic Article
Nov 30, 2023
Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
|
-
Negative Delta-Prostate-Specific Antigen Time Ratio as Potential New Marker of Progression-Free Survival in Castration-Resistant Prostate Cancer Patients Treated With First-Line Enzalutamide or Docetaxel
- Tae Hwan Kim, Seol Ho Choo, Kang Hee Shim, et al.
-
J Urol Oncol. 2023;21(3):271-276.
-
Original Article
Nov 30, 2023
Clinical Predictors of ARTA Response in Metastatic Prostate Cancer
|
-
Clinical Significance of Rab27a as a Urinary Biomarker in Patients With Bladder Cancer
- Ja Yoon Ku, Md Nazmul Huda, Eu Chang Hwang, et al.
-
J Urol Oncol. 2023;21(3):277-277.
Corrects: J Urol Oncol 2022;20(1):52
-
Erratum: Addition of the second author
Nov 30, 2023
|